Linagliptin is a pharmaceutical compound used as an active pharmaceutical ingredient in products for managing type 2 diabetes. It functions as a dipeptidyl peptidase-4 inhibitor, helping to regulate insulin and glucagon production by the pancreas.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 668270-12-0
7-(2-Butyn-1-yl)-8-[(3R)-3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-piperidinyl]-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione
pharmaceutical intermediate
Halobetasol propionate
pharmaceutical raw material
Calcium gluconate monohydrate
pharmaceutical raw material
(3,4-Diaminophenyl)(4-fluorophenyl)methanone
pharmaceutical raw material
Tianeptine
pharmaceutical raw material
1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl-4,4,4-d3)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-; 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butyn-1-yl-4,4,4-d3)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-p
pharmaceutical raw material
LINAGLIPTIN, (S)-
pharmaceutical raw material
[(3R)-1-[7-(2-Butynyl)-2,3,6,7-tetrahydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]carbamic acid 1,1-dimethylethyl ester
pharmaceutical intermediate
8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
LTXREWYXXSTFRX-QGZVFWFLSA-N
CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C